English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

CS-834 is a prodrug of the carbapenem R-95867, developed by Sankyo Co., Ltd., Tokyo, Japan. To investigate the possibility that CS-834 may be the first carbapenem usable in an oral dosage form, its in vitro antibacterial activity (as R-95867) and in vivo antibacterial activity were compared with those of cefpodoxime proxetil, cefditoren pivoxil, cefdinir, ofloxacin, imipenem, and amoxicillin. R-95867 had high levels of activity against methicillin-susceptible staphylococci and streptococci, including penicillin-resistantStreptococcus pneumoniae , as well asNeisseria gonorrhoeae ,Moraxella catarrhalis , the members of the familyEnterobacteriaceae (with the exception ofSerratia marcescens ),Haemophilus influenzae , andBordetella pertussis ; for all these strains, the MICs at which 90% of tested strains are inhibited (MIC90 s) were 1.0 μg/ml or less. Against methicillin-resistant staphylococci, enterococci,Serratia marcescens ,Brukholderia cepacia ,Stenotrophomonas maltophilia , andAcinetobacter calcoaceticus , R-95867 showed activity comparable to or slightly less than that of imipenem, with MIC90 s ranging from 2 to &gt;128 μg/ml. The in vivo efficacy of oral CS-834 against experimental mouse septicemia caused by gram-positive and gram-negative bacteria was better than that of comparative drugs. In murine respiratory infection models, the efficacy of CS-834 reflected not only its potent in vitro activity but also the high levels present in the lungs.

In Vitro and In Vivo Antibacterial Activities of CS-834, a New Oral Carbapenem